Sulfonylurea action re‐revisited

Sulfonylureas (SU), commonly used in the treatment of type 2 diabetes mellitus (T2DM), stimulate insulin secretion by inhibiting adenosine triphosphate (ATP)‐sensitive K(+) (K(ATP)) channels in pancreatic β‐cells. SU are now known to also activate cyclic adenosine monophosphate (cAMP) sensor Epac2 (...

Descripción completa

Detalles Bibliográficos
Autores principales: Seino, Susumu, Zhang, Chang‐Liang, Shibasaki, Tadao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2010
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4020675/
https://www.ncbi.nlm.nih.gov/pubmed/24843406
http://dx.doi.org/10.1111/j.2040-1124.2010.00014.x
Descripción
Sumario:Sulfonylureas (SU), commonly used in the treatment of type 2 diabetes mellitus (T2DM), stimulate insulin secretion by inhibiting adenosine triphosphate (ATP)‐sensitive K(+) (K(ATP)) channels in pancreatic β‐cells. SU are now known to also activate cyclic adenosine monophosphate (cAMP) sensor Epac2 (cAMP‐GEFII) to Rap1 signaling, which promotes insulin secretion. The different effects of various SU on Epac2/Rap1 signaling, as well as K(ATP) channels in different tissues, underlie the diverse pancreatic and extra‐pancreatic actions of SU. (J Diabetes Invest, doi: 10.1111/j.2040‐1124.2010.00014.x, 2010)

Ejemplares similares